|
Latest Publications Tan L., Lovejoy DA (2009) Neuroprotection, neuronal remodelling, and anxiety-like behaviour: The role of the teneurin and teneurin C-terminal associated peptide (TCAP) system in the hippocampus. American Journal of Neuroprotection and Neuroregeneration. 1: 3-10. Tan L, Xu K, Vaccarino FJ, Lovejoy DA, Rotzinger S (2009) Teneurin C-terminal associated peptide (TCAP)-1 attenuates corticotropin-releasing factor (CRF)-induced c-Fos expression in the limbic system and modulates anxiety behaviour in male Wistar rats Behavioural Brain Research 201, 198-206. Lovejoy DA, Rotzinger S, Barsyte-Lovejoy, D (2009) Evolution of complementary peptide systems: Teneurin C-terminal associated peptide (TCAP) and corticotropin-releasing factor (CRF) superfamilies. Annals of the New York Academy of Sciences. 1163, 215-220. The information posted here was accurate at the time of posting, but may be superseded by subsequent releases. 2012 May 23, 2012 United States Patent Number 8,088,889 issued for “TENEURIN C-TERMINAL ASSOCIATED PEPTIDES (TCAP) AND USES THEREOF”.
2011 May 25, 2011 Protagenic Therapeutics to Present at the BioFinance 2011 Conference. January 17, 2011 Australian Patent Number 2003221575 issued for “TENEURIN C-TERMINAL ASSOCIATED PEPTIDES (TCAP) AND USES THEREOF”. 2008 September 22, 2008 Protagenic Therapeutics to Present at the BioContact 2008 Symposium. April 18 2008 Letter to Shareholders. March 20 2008 Protagenic Therapeutics Raised Approximately $1 Million Through Private Placement.
2005 February 19 2005 Globe and Mail
|
 |
